Navigation Links
National Institute of Health Awards Contract to Support Use of iBio's Proprietary Technology for Improved Anthrax Vaccine
Date:12/5/2012

NEWARK, Del., Dec. 5, 2012 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) announced today that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a contract to the Company's research and development collaborator, the Fraunhofer USA Center for Molecular Biotechnology, for a new generation anthrax vaccine to be developed with the iBioLaunch™ Platform under a research license from iBio. The first year of funding will be $1.76 million with a total contract amount of up to $9.9 million, depending on the exercise of contract options.

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

In October 2012, iBio announced issuance of a U.S. patent covering compositions of matter and methods of producing anthrax vaccines, an expansion of the Company's portfolio of assets relevant to bio-defense and infectious disease product applications. Data previously published in peer-reviewed scientific journals demonstrated the effectiveness of the iBioLaunch platform for development and production of vaccine candidates for both bacterial pathogens, such as plague and anthrax, and viral pathogens such as influenza and human papilloma virus.

"The award of this contract to Fraunhofer is an important expression of confidence in the importance of our iBioLaunch and iBioModulator™ technologies," said Terence Ryan, iBio's Chief Scientific Officer. "We believe that our portfolio of highly protective anthrax vaccines and monoclonal antibodies, along with this expanded anthrax initiative, will generate significant commercial interest in other novel applications of our technology."

iBio's strategy for development of therapeutic and vaccine product applications of its technology platforms is through commercial collaboration and licensing internationally with corporations and government entities. In September 2012, iBio and GE Healthcare announced the formation of a new global alliance, and the Company's technology is being used for development of a new recombinant yellow fever vaccine under a commercial license and product development collaboration with Fiocruz/Bio-Manguinhos. Phase 1 clinical trials of influenza vaccine candidates produced via the iBioLaunch platform were funded by the U.S. Department of Defense and the Bill & Melinda Gates Foundations. iBio previously announced success in the use of its platform for the production of a variety of therapeutic protein candidates including monoclonal antibodies and human blood plasma proteins. The Company is currently seeking additional partners for new vaccine candidates and for biotherapeutic products based on its platform technologies.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products.

The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.

The iBioModulator  platform is complementary to the iBioLaunch platform and enables significantly improved vaccine products with higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as lack of available capital, intellectual property protection issues, competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

Contacts:

Corporate:

Robert Erwin, President
iBio, Inc.
302-355-2335
rerwin@ibioinc.com

Investor:

Douglas Beck, CFO
iBio, Inc.
302-355-9452
ir@ibioinc.com


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
6. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
7. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
8. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
9. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
10. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
11. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and Markets has announced the addition of the "Vital Signs Monitoring ... Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size was worth $3,694 ... growing at a CAGR of 5.8% from 2016 to 2022. ... in global vital signs monitoring devices industry. The blood pressure monitoring devices ...
(Date:1/18/2017)... SAN JOSE, Calif. , Jan. 18, 2017  Adaptive ... machines, announced today a new partnership with Hyatt Place ... guests by providing ASTI LectroFan sleep therapy machines in ... "Obviously one of the most important parts of having ... Wicks , general manager of Hyatt Place Nashville/Downtown. "We,re ...
(Date:1/18/2017)... LITTLE FALLS, N.J. , Jan. 18, 2017 /PRNewswire/ ... RGIN ), a biotechnology company specializing in the development ... health of damaged tissues and organs, recently reported the ... key milestones for 2017. As the Company ... 2016 has been a year of substantial accomplishments. The ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish ... a condensed version of the clinic’s leading recovery program. , “We know ...
(Date:1/19/2017)... ... 19, 2017 , ... Bio-Optronics Inc. is proud to announce ... designed to seamlessly integrate and streamline the way researchers prepare and conduct patient ... usability and improving efficiency significantly for users – a first in the CTMS ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):